Inrebic and Itching - a phase IV clinical study of FDA data

Summary:

Itching is reported as a side effect among people who take Inrebic (fedratinib hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Jakafi, and have Primary myelofibrosis.

The phase IV clinical study analyzes which people have Itching when taking Inrebic. It is created by eHealthMe based on reports of 1,138 people who have side effects when taking Inrebic from the FDA, and is updated regularly.

What is Inrebic?

Inrebic has active ingredients of fedratinib hydrochloride. eHealthMe is studying from 1,138 Inrebic users. Check the latest studies of Inrebic.

What is Itching?

Itching is found to be associated with 3,211 drugs and 4,538 conditions by eHealthMe. Check the latest studies of Itching.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

1,138 people reported to have side effects when taking Inrebic.
Among them, 31 people (2.72%) have Itching.

Among these 31 people:

How long have people been on Inrebic when they have Itching? *

What is the gender of people who have Itching when taking Inrebic? *

female: 44.83 %
male: 55.17 %

What is the age of people who have Itching when taking Inrebic? *

What are other drugs people take besides Inrebic? *

What are other side effects people have besides Itching? *

Diarrhea: 5 people, 16.13%
Burning Sensation: 5 people, 16.13%
Headache (pain in head): 4 people, 12.90%
Haemoglobin Decreased: 4 people, 12.90%
Fatigue (feeling of tiredness): 4 people, 12.90%
Bone Pain: 4 people, 12.90%
Thrombocytopenia (decrease of platelets in blood): 3 people, 9.68%
Dizziness: 3 people, 9.68%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 9.68%
Constipation: 3 people, 9.68%

What are the existing conditions these people have? *

Primary Myelofibrosis (primary disorder of the bone marrow): 17 people, 54.84%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 2 people, 6.45%
Polycythaemia (proportion of blood volume that is occupied by red blood cells increases): 2 people, 6.45%
Pain: 2 people, 6.45%
Urticaria (rash of round, red welts on the skin that itch intensely): 1 person, 3.23%
Splenomegaly (enlargement of spleen): 1 person, 3.23%
Neoplasm Malignant (cancer tumour): 1 person, 3.23%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 3.23%
Blood Count Abnormal: 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Inrebic and have Itching?

- Check whether Itching is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inrebic:

Inrebic (1,138 reports)

Itching treatments and more:

Itching (398,823 reports)

Browse all side effects of Inrebic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Itching:

Itching (3,211 drugs)

Browse all the conditions that are associated with Itching:

Itching (4,538 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fedratinib hydrochloride (the active ingredients of Inrebic) and Inrebic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.